333 related articles for article (PubMed ID: 38195781)
21. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.
Tang L; Huang Z; Mei H; Hu Y
Signal Transduct Target Ther; 2023 Aug; 8(1):306. PubMed ID: 37591844
[TBL] [Abstract][Full Text] [Related]
22. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
23. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Pennock GK; Chow LQ
Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
[TBL] [Abstract][Full Text] [Related]
24. Outcome Prediction and Evaluation by Imaging the Key Elements of Therapeutic Responses to Cancer Immunotherapies Using PET.
Bu L; Sun Y; Han G; Tu N; Xiao J; Wang Q
Curr Pharm Des; 2020; 26(6):675-687. PubMed ID: 31465273
[TBL] [Abstract][Full Text] [Related]
25. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
[TBL] [Abstract][Full Text] [Related]
26. Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era.
Klener P; Etrych T; Klener P
Curr Med Chem; 2019; 26(6):1002-1018. PubMed ID: 28990505
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Advances in Immunotherapies for Hematological Malignancies.
Nogami A; Sasaki K
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232824
[TBL] [Abstract][Full Text] [Related]
28. [Recent advances and future challenges in cancer immunotherapy].
Okuyama N; Tamada K; Tamura H
Rinsho Ketsueki; 2016; 57(11):2388-2395. PubMed ID: 27941290
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
30. Clinical cancer immunotherapy: Current progress and prospects.
Liu C; Yang M; Zhang D; Chen M; Zhu D
Front Immunol; 2022; 13():961805. PubMed ID: 36304470
[TBL] [Abstract][Full Text] [Related]
31. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
Ni K; Luo T; Nash GT; Lin W
Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
[TBL] [Abstract][Full Text] [Related]
32. Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics.
Abaza A; Sid Idris F; Anis Shaikh H; Vahora I; Moparthi KP; Al Rushaidi MT; Muddam MR; Obajeun OA; Jaramillo AP; Khan S
Cureus; 2023 Sep; 15(9):e44582. PubMed ID: 37667784
[TBL] [Abstract][Full Text] [Related]
33. The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma.
Liu X; Zhao Z; Dai W; Liao K; Sun Q; Chen D; Pan X; Feng L; Ding Y; Wei S
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686584
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives.
Koustas E; Trifylli EM; Sarantis P; Papadopoulos N; Karapedi E; Aloizos G; Damaskos C; Garmpis N; Garmpi A; Papavassiliou KA; Karamouzis MV; Papavassiliou AG
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743107
[TBL] [Abstract][Full Text] [Related]
35. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
Inthagard J; Edwards J; Roseweir AK
Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy as an Option for Cancer Treatment.
Rusch T; Bayry J; Werner J; Shevchenko I; Bazhin AV
Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):89-96. PubMed ID: 29026920
[TBL] [Abstract][Full Text] [Related]
38. Immune escape mechanisms and immunotherapy of urothelial bladder cancer.
Yang Z; Xu Y; Bi Y; Zhang N; Wang H; Xing T; Bai S; Shen Z; Naz F; Zhang Z; Yin L; Shi M; Wang L; Wang L; Wang S; Xu L; Su X; Wu S; Yu C
J Clin Transl Res; 2021 Aug; 7(4):485-500. PubMed ID: 34541363
[TBL] [Abstract][Full Text] [Related]
39. Enhancing Cancer Chemo-Immunotherapy: Innovative Approaches for Overcoming Immunosuppression by Functional Nanomaterials.
Wang J; Li L; Xu ZP
Small Methods; 2024 Jan; 8(1):e2301005. PubMed ID: 37743260
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapeutic Agents for Intratumoral Immunotherapy.
Shyr CR; Liu LC; Chien HS; Huang CP
Vaccines (Basel); 2023 Nov; 11(11):. PubMed ID: 38006049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
